Management of EGFR mutation-positive non-small cell lung cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue , 2016, Pages 672-674

  Lilenbaum, Rogerio A ^a   Horn, Leora A ^b  

^a YALE CANCER CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MUTATION; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84995773041     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0189     Document Type: Conference Paper

References (4)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
2. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 23 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-151.
3. Park K, Tan EH, Zhang L, et al. Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7) [abstract]. Ann Oncol 2015;26(Suppl 9):ix61-62. Abstract LBA2-PR.
4. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015;16:990-998.